Compare Gilead Sciences, Inc. (GILD) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Jumia Technologies AG - ADR — how do they compare? Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B), while Jumia Technologies AG - ADR trades at $6.4 (market cap $865.90M). The key difference: Gilead Sciences, Inc. is far larger — about 210.6× Jumia Technologies AG - ADR's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Jumia Technologies AG - ADR for 28 Days on average.
| GILD | JMIA | |
|---|---|---|
Market Cap | $182.40B | $865.90M |
Volume | 4,469,821 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $14.60 |
52-Week Low | $116.74 | $5.69 |
Typical Hold Time | 111 Days | 28 Days |
Enterprise Value | $205.46B | $831.54M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
JMIA stock trades at $6.28, down 6.82% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $167M in 2024 to $189M in 2025 and narrowing losses. Analyst consensus remains strong with 71% buy ratings and a $12.00 price target, supported by recent $50M capital infusion and path to EBITDA breakeven.
The outlook suggests potential upside if JMIA achieves profitability targets, but risks include persistent negative margins, high P/B ratio of 975, and competitive pressures in African e-commerce. The stock offers speculative growth potential with significant execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
